Amneal Pharmaceuticals Q4 Earnings Summary & Key Takeaways
Amneal Pharmaceuticals, Inc. Class A AMRX | 12.32 12.32 | -0.24% 0.00% Post |
The Q4 earnings report for Amneal Pharmaceuticals (NASDAQ:AMRX) was released on Friday, February 27, 2026 at 06:00 AM.
Here's what investors need to know about the latest announcement.
Earnings
Amneal Pharmaceuticals beat estimated earnings by 16.67%, reporting an EPS of $0.21 versus an estimate of $0.18.
Revenue was up $83.80 million from the same period last year.
Historical Earnings Summary
The company beat on EPS by $0.04 in the last quarter, resulting in a 8.2% increase share price change the following day.
Here's a look at Amneal Pharmaceuticals's past performance:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | 0.13 | 0.17 | 0.15 | 0.15 |
| EPS Actual | 0.17 | 0.25 | 0.21 | 0.12 |
| Revenue Estimate | 773.73M | 736.98M | 715.49M | 708.07M |
| Revenue Actual | 784.51M | 725.00M | 695.42M | 730.52M |
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Guidance
Amneal Pharmaceuticals management provided guidance for FY 2026, expecting earnings between $0.93 and $1.03 per share.
To track all earnings releases for Amneal Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.